Giovanni Coticchio Ph.D. , Danilo Cimadomo Ph.D. , Michel De Vos M.D., Ph.D. , Thomas Ebner Ph.D. , Marga Esbert Ph.D. , Maria Jose Escribá Ph.D. , Robert B. Gilchrist D.Sc. , Laura Rienzi Ph.D.
{"title":"To rescue or not to rescue immature oocytes: prospects and challenges","authors":"Giovanni Coticchio Ph.D. , Danilo Cimadomo Ph.D. , Michel De Vos M.D., Ph.D. , Thomas Ebner Ph.D. , Marga Esbert Ph.D. , Maria Jose Escribá Ph.D. , Robert B. Gilchrist D.Sc. , Laura Rienzi Ph.D.","doi":"10.1016/j.fertnstert.2025.02.039","DOIUrl":null,"url":null,"abstract":"<div><div>In vitro maturation (IVM) of immature oocytes has been explored for research and clinical purposes since the dawn of assisted reproductive technologies. Oocyte maturation is a highly specific process, on the basis of complex mutual relationships between the germ and somatic cell compartments. The complexity of this relationship has made the quest for achieving oocyte maturation in vitro arduous. In its classical form, in which intact cumulus-enclosed oocytes are collected after very mild or no ovarian stimulation, oocyte IVM is nonexperimental and has been proposed as a more friendly treatment for patients with polycystic ovary or polycystic ovary syndrome. By contrast, rescue IVM (r-IVM), which is the maturation in vitro of immature oocytes collected in standard ovarian stimulation cycles, is an experimental procedure, proposed to mitigate the impact of low oocyte maturation rates in certain patients. Achieving effective r-IVM has turned out to be an even more daunting task because oocytes are cultured only after cumulus cell removal and, therefore, without the crucial somatic metabolic and regulative support. Immature oocyte arrested at the germinal vesicle or metaphase I stage require different management for their maturation in vitro and exhibit different developmental and chromosomal competence. Therefore, their possible use for treatment suggests a dedicated approach. Overall, r-IVM has limited clinical efficacy due to suboptimal maturation and developmental competence of immature oocytes. This raises a cost/benefit question: that is, the definition of appropriate clinical indications. Rescue IVM is probably irrelevant to treatment cycles in which the absolute number of mature oocytes is high. Conversely, specific poor prognosis cases, involving low maturation rates, low oocyte yield, and/or low oocyte quality, could benefit from the contribution of even a single embryo generated from an in vitro matured oocyte. Future progress in this field will depend on our ability to mimic in vitro the support provided by cumulus cells to oocyte nuclear and cytoplasmic maturation.</div></div>","PeriodicalId":12275,"journal":{"name":"Fertility and sterility","volume":"123 5","pages":"Pages 749-758"},"PeriodicalIF":7.0000,"publicationDate":"2025-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Fertility and sterility","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0015028225001475","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
In vitro maturation (IVM) of immature oocytes has been explored for research and clinical purposes since the dawn of assisted reproductive technologies. Oocyte maturation is a highly specific process, on the basis of complex mutual relationships between the germ and somatic cell compartments. The complexity of this relationship has made the quest for achieving oocyte maturation in vitro arduous. In its classical form, in which intact cumulus-enclosed oocytes are collected after very mild or no ovarian stimulation, oocyte IVM is nonexperimental and has been proposed as a more friendly treatment for patients with polycystic ovary or polycystic ovary syndrome. By contrast, rescue IVM (r-IVM), which is the maturation in vitro of immature oocytes collected in standard ovarian stimulation cycles, is an experimental procedure, proposed to mitigate the impact of low oocyte maturation rates in certain patients. Achieving effective r-IVM has turned out to be an even more daunting task because oocytes are cultured only after cumulus cell removal and, therefore, without the crucial somatic metabolic and regulative support. Immature oocyte arrested at the germinal vesicle or metaphase I stage require different management for their maturation in vitro and exhibit different developmental and chromosomal competence. Therefore, their possible use for treatment suggests a dedicated approach. Overall, r-IVM has limited clinical efficacy due to suboptimal maturation and developmental competence of immature oocytes. This raises a cost/benefit question: that is, the definition of appropriate clinical indications. Rescue IVM is probably irrelevant to treatment cycles in which the absolute number of mature oocytes is high. Conversely, specific poor prognosis cases, involving low maturation rates, low oocyte yield, and/or low oocyte quality, could benefit from the contribution of even a single embryo generated from an in vitro matured oocyte. Future progress in this field will depend on our ability to mimic in vitro the support provided by cumulus cells to oocyte nuclear and cytoplasmic maturation.
期刊介绍:
Fertility and Sterility® is an international journal for obstetricians, gynecologists, reproductive endocrinologists, urologists, basic scientists and others who treat and investigate problems of infertility and human reproductive disorders. The journal publishes juried original scientific articles in clinical and laboratory research relevant to reproductive endocrinology, urology, andrology, physiology, immunology, genetics, contraception, and menopause. Fertility and Sterility® encourages and supports meaningful basic and clinical research, and facilitates and promotes excellence in professional education, in the field of reproductive medicine.